AstraZeneca Aiming To Extend Brilinta Use In PCI patients
Executive Summary
AstraZeneca PLC’s newer oncology treatments are currently powering its growth, but the company is also looking to its cardiovascular, renal & metabolism (CVRM) portfolio to contribute, and a new study of Brilinta will help.